FILANA THERAPEUTICS, INC. - Common Stock (FLNA)
CUSIP: 14817C107
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 48,331,225
- Total 13F shares
- 12,246,863
- Share change
- -3,522,961
- Total reported value
- $22,166,624
- Put/Call ratio
- 64%
- Price per share
- $1.81
- Number of holders
- 96
- Value change
- -$6,209,960
- Number of buys
- 39
- Number of sells
- 69
Quarterly Holders Quick Answers
What is CUSIP 14817C107?
CUSIP 14817C107 identifies FLNA - FILANA THERAPEUTICS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 14817C107:
Top shareholders of FLNA - FILANA THERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Sanford Robertson |
3/4/5
|
Director |
—
mixed-class rows
|
1,531,591
mixed-class rows
|
$25,241,772 | — | 16 May 2024 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
3.2%
from 13D/G
|
3,474,980
|
$5,212,472 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13D/G
13F
|
The Vanguard Group · Company |
4.5%
|
2,170,072
|
$3,927,830 | $0 | 30 Jun 2025 | |
| Nachtrab Matthew |
13D/G
|
— |
4.7%
|
2,267,636
|
$3,560,189 | $0 | 16 Aug 2024 | |
| Nuveen, LLC |
13F
|
Company |
0.14%
|
69,200
|
$1,952,407 | — | 31 Mar 2025 | |
| Freda Nassif |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
100,000
|
$1,687,000 | — | 17 Apr 2025 | |
| James William Kupiec |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
100,000
|
$1,687,000 | — | 29 Nov 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
1,026,599
|
$1,540,269 | — | 31 Mar 2025 | |
| Jaren Landen |
3/4/5
|
Chief Clinical Dev. Officer |
—
class O/S missing
|
85,000
|
$1,433,950 | — | 18 Nov 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.9%
|
908,600
|
$1,362,900 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
873,946
|
$1,310,919 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.6%
|
790,016
|
$1,185,025 | — | 31 Mar 2025 | |
| Remi Barbier |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
50,000
|
$843,500 | — | 20 May 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.1%
|
552,021
|
$828,032 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
1.1%
|
545,815
|
$818,723 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1%
|
496,313
|
$744,470 | — | 31 Mar 2025 | |
| GMT CAPITAL CORP |
13F
|
Company |
0.93%
|
450,100
|
$675,150 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.9%
|
432,581
|
$648,872 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.78%
|
376,350
|
$564,528 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.76%
|
369,090
|
$553,636 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.75%
|
361,253
|
$541,880 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.57%
|
276,835
|
$415,253 | — | 31 Mar 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.42%
|
201,890
|
$302,835 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.41%
|
200,000
|
$300,000 | — | 31 Mar 2025 | |
| Robert Z. Gussin |
3/4/5
|
Director |
—
class O/S missing
|
26,500
|
$253,050 | — | 23 May 2025 | |
| Verition Fund Management LLC |
13F
|
Company |
0.28%
|
135,166
|
$202,749 | — | 31 Mar 2025 | |
| STRS OHIO |
13F
|
Company |
0.25%
|
118,900
|
$178,350 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.24%
|
116,820
|
$175,231 | — | 31 Mar 2025 | |
| Claude Nicaise |
3/4/5
|
Director |
—
class O/S missing
|
26,500
|
$168,700 | — | 23 May 2025 | |
| Michael J. O Donnell |
3/4/5
|
Director |
—
class O/S missing
|
26,500
|
$168,700 | — | 23 May 2025 | |
| Patrick J. MD Scannon PhD |
3/4/5
|
Director |
—
class O/S missing
|
26,500
|
$168,700 | — | 23 May 2025 | |
| Pierre Gravier |
3/4/5
|
Director |
—
class O/S missing
|
26,500
|
$168,700 | — | 23 May 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.23%
|
110,658
|
$165,987 | — | 31 Mar 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.2%
|
94,925
|
$142,388 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.19%
|
90,241
|
$135,362 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.17%
|
79,944
|
$119,917 | — | 31 Mar 2025 | |
| Gallacher Capital Management LLC |
13F
|
Company |
0.14%
|
69,660
|
$104,490 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.13%
|
65,124
|
$97,686 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.12%
|
58,958
|
$88,431 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.11%
|
55,397
|
$83,096 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.11%
|
53,134
|
$79,701 | — | 31 Mar 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.11%
|
52,353
|
$78,530 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.09%
|
44,130
|
$66,196 | — | 31 Mar 2025 | |
| Walleye Trading LLC |
13F
|
Company |
0.09%
|
42,895
|
$64,343 | — | 31 Mar 2025 | |
| Apollon Wealth Management, LLC |
13F
|
Company |
0.08%
|
40,237
|
$60,356 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.08%
|
37,410
|
$56,115 | — | 31 Mar 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.08%
|
37,257
|
$55,882 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.08%
|
37,000
|
$55,500 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.07%
|
34,615
|
$51,923 | — | 31 Mar 2025 | |
| INTECH INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.07%
|
32,895
|
$49,343 | — | 31 Mar 2025 |
Institutional Holders of FILANA THERAPEUTICS, INC. - Common Stock (FLNA) as of Q2 2025
As of 30 Jun 2025,
FILANA THERAPEUTICS, INC. - Common Stock (FLNA) was held by
96 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,246,863 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., TWO SIGMA ADVISERS, LP, JPMORGAN CHASE & CO, GOLDMAN SACHS GROUP INC, TWO SIGMA INVESTMENTS, LP, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, MORGAN STANLEY, and GMT CAPITAL CORP.
This page lists
95
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
114
Q2 2025 holders
96
Holder diff
-18
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.